Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 May;180(5):1183-1189.
doi: 10.1111/bjd.17312. Epub 2018 Dec 5.

Prediction of disease relapse in a cohort of paediatric patients with localized scleroderma

K L Kurzinski  1 , C K Zigler  2   3 , K S Torok  1
Affiliations

Prediction of disease relapse in a cohort of paediatric patients with localized scleroderma

K L Kurzinski et al. Br J Dermatol. 2019 May.

Abstract

Background: Localized scleroderma (LS) is an autoimmune condition of the skin and underlying tissue. Active or recurring disease can lead to cumulative tissue damage, especially in paediatric-onset disease.

Objectives: To highlight the rate of relapse of LS activity in a cohort of paediatric patients and to evaluate for potential clinical and laboratory predictors of disease relapse.

Methods: Clinical and laboratory data were gathered prospectively. Patients were categorized as experiencing relapse or not, and clinical and laboratory parameters were compared. A logistic regression was fit to predict odds of relapse while controlling for multiple predictors. A subgroup of patients was also evaluated to determine the average time from treatment completion to relapse.

Results: Seventy-seven patients were followed for the identified study duration of > 2 years and had achieved disease remission, with 35 (45%) experiencing LS relapse. Patients who were older at disease onset, antinuclear antibody (ANA) positive and without an extracutaneous manifestation (ECM) were more likely to relapse. All three variables remained significant in the multivariable logistic regression model. Results of the subgroup mirrored the larger sample. The average time between treatment completion and relapse was 21 months.

Conclusions: Assessment of patients with LS experiencing a relapse of disease activity has shown older age of initial LS onset and ANA positivity to be potential markers for risk of relapse. Patients meeting these parameters may require greater clinical vigilance. The presence of one or more ECM may be protective. Clinicians treating patients with LS should provide significant long-term follow-up to monitor for relapse.

PubMed Disclaimer

Conflict of interest statement

Disclosures:

The authors do not have any conflicts of interest to disclose.

Comment in

References

    1. Arkachaisri T, Vilaiyuk S, Li S, O’Neil KM, Pope E, Higgins GC, Punaro M, Rabinovich EC, Rosenkranz M, Kietz DA, Rosen P, Spalding SJ, Hennon TR, Torok KS, Cassidy E, Medsger TA Jr., Localized Scleroderma C, Ultrasound Study G. The localized scleroderma skin severity index and physician global assessment of disease activity: a work in progress toward development of localized scleroderma outcome measures. J Rheumatol 2009;36(12):2819–29. Epub 2009/10/17. doi: 10.3899/jrheum.081284. - DOI - PMC - PubMed
    1. Li SC, Torok KS, Pope E, Dedeoglu F, Hong S, Jacobe HT, Rabinovich CE, Laxer RM, Higgins GC, Ferguson PJ, Lasky A, Baszis K, Becker M, Campillo S, Cartwright V, Cidon M, Inman CJ, Jerath R, O’Neil KM, Vora S, Zeft A, Wallace CA, Ilowite NT, Fuhlbrigge RC, Childhood A, Rheumatology Research Alliance Localized Scleroderma W. Development of consensus treatment plans for juvenile localized scleroderma: a roadmap toward comparative effectiveness studies in juvenile localized scleroderma. Arthritis Care Res (Hoboken) 2012;64(8):1175–85. Epub 2012/04/17. doi: 10.1002/acr.21687. - DOI - PMC - PubMed
    1. Peterson LS, Mason T, Nelson AM, O’Fallon WM, Gabriel SE. Psychosocial outcomes and health status of adults who have had juvenile rheumatoid arthritis: a controlled, population-based study. Arthritis Rheum 1997;40(12):2235–40. Epub 1998/01/07. doi: 10.1002/1529-0131(199712)40:12<2235::AID-ART18>3.0.CO;2-F. - DOI - PubMed
    1. Zulian F, Athreya BH, Laxer R, Nelson AM, Feitosa de Oliveira SK, Punaro MG, Cuttica R, Higgins GC, Van Suijlekom-Smit LW, Moore TL, Lindsley C, Garcia-Consuegra J, Esteves Hilario MO, Lepore L, Silva CA, Machado C, Garay SM, Uziel Y, Martini G, Foeldvari I, Peserico A, Woo P, Harper J, Juvenile Scleroderma Working Group of the Pediatric Rheumatology European S. Juvenile localized scleroderma: clinical and epidemiological features in 750 children. An international study. Rheumatology (Oxford) 2006;45(5):614–20. Epub 2005/12/22. doi: 10.1093/rheumatology/kei251. - DOI - PubMed
    1. Zulian F, Vallongo C, Woo P, Russo R, Ruperto N, Harper J, Espada G, Corona F, Mukamel M, Vesely R, Musiej-Nowakowska E, Chaitow J, Ros J, Apaz MT, Gerloni V, Mazur-Zielinska H, Nielsen S, Ullman S, Horneff G, Wouters C, Martini G, Cimaz R, Laxer R, Athreya BH, Juvenile Scleroderma Working Group of the Pediatric Rheumatology European S. Localized scleroderma in childhood is not just a skin disease. Arthritis Rheum 2005;52(9):2873–81. Epub 2005/09/06. doi: 10.1002/art.21264. - DOI - PubMed

Publication types

MeSH terms